Respite for hybrid coronary revascularization

Abstract

Hybrid coronary revascularization incorporates a surgical anastomosis of the left internal mammary artery to the left anterior descending coronary artery through a thoracotomy and percutaneous implantation of drug eluting stents in diseased non-left anterior descending coronary arteries. Hybrid coronary artery revascularization can be performed as a 1-stage procedure in a hybrid operating room or as a tightly scheduled 2-stage procedure. Hybrid coronary artery revascularization is seldom the selected modality for coronary revascularization due to the lack of a hybrid operating room in many hospitals, the recommended thoracotomy approach for bypass, or the rigid schedule of surgical and endovascular revascularization. A 2-stage approach, using a sternotomy as compared to standard thoracotomy, and a flexible schedule between surgical and endovascular procedures may facilitate the adoption of hybrid coronary revascularization with non-complex multi-vessel stable coronary artery disease.

Keywords

Hybrid / coronary artery bypass / revascularization / multi-vessel / saphenous vein graft / left anterior mammary artery / percutaneous coronary intervention

References

[1] Koskinas KC,Räber L.Regression of coronary atherosclerosis: current evidence and future perspectives..Trends Cardiovasc Med2016;26:150-61

[2] Nissen SE,Schoenhagen P,Ganz P.Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial..JAMA2004;291:1071-80

[3] Nissen SE,Sipahi I,Raichlen JS.Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial..JAMA2006;295:1556-65

[4] Nicholls SJ,Barter PJ,Erbel RM.Effect of two intensive statin regimens on progression of coronary disease..N Engl J Med2011;365:2078-87

[5] VA Coronary Artery Bypass Surgery Cooperative Study GroupEighteen-year follow-up in the veterans affairs cooperative study of coronary artery bypass surgery for stable angina..Circulation1992;86:121-30

[6] Fihn SD,Abrams J,Blankenship JC.2012ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons..J Am Coll Cardiol2012;60:e44-164

[7] Serruys PW,van Herwerden LA,Jatene A.Five-year outcomes after coronary stenting versus bypass surgery for the treatment of multivessel disease: the final analysis of the Arterial Revascularization Therapies Study (ARTS) randomized trial..J Am Coll Cardiol2005;46:575-81

[8] Park SJ,Kim YH,Yun SC.Trial of everolimus-eluting stents or bypass surgery for coronary disease..N Engl J Med2015;372:1204-12

[9] Kapur A,Malik IS,Butts J.Randomized comparison of percutaneous coronary intervention with coronary artery bypass grafting in diabetic patients. 1-year results of the CARDia (Coronary Artery Revascularization in Diabetes) trial..J Am Coll Cardiol2010;55:432-40

[10] Farkouh ME,Sleeper LA,Dangas G.Strategies for multivessel revascularization in patients with diabetes..N Engl J Med2012;367:2375-84

[11] Hueb W,Gersh BJ,Machado LA.Five-year follow-up of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease..Circulation2007;115:1082-9

[12] Serruys PW,Kappetein AP,Holmes DR.Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease..N Engl J Med2009;360:961-72

[13] Hou L,Hakeem A.A physiological approach to refine appropriateness of revascularization, clinical decision making and prognosis in patients with multi vessel coronary artery disease..J Thorac Dis2018;10:5661-5 PMCID:PMC6236180

[14] Mehta RH,Shaw LK,Smith PK.Clinical and angiographic correlates of short- and long-term mortality in patients undergoing coronary artery bypass grafting..Am J Cardiol2007;100:1538-42

[15] Goldman S,Moritz T,Sethi G.Long-term patency of saphenous vein and left internal mammary artery grafts after coronary artery bypass surgery: results from a Department of Veterans Affairs Cooperative Study..J Am Coll Cardiol2004;44:2149-56

[16] Meng M,Wang X,Sa RN.Long-term clinical outcomes of everolimus-eluting stent versus paclitaxel-eluting stent in patients undergoing percutaneous coronary interventions: a meta-analysis..BMC Cardiovasc Disord2016;16:34 PMCID:PMC4748592

[17] Mehta RH,Peterson ED,Halabi AR.Impact of internal mammary artery conduit on long-term outcomes after percutaneous intervention of saphenous vein graft..Circulation2006;114:I396-401

[18] Saha T,Goldberg S.Hybrid revascularization: a review..Cardiology2018;140:35-44

[19] Gąsior M,Tajstra M,Gierlotka M.Hybrid revascularization for multivessel coronary artery disease..JACC Cardiovasc Interv2014;7:1277-83

[20] Harskamp RE,Xian Y,Puskas JD.Practice patterns and clinical outcomes after hybrid coronary revascularization in the United States: an analysis from the society of thoracic surgeons adult cardiac database..Circulation2014;130:872-9

[21] Squiers JJ.Coronary artery bypass grafting-fifty years of quality initiatives since Favaloro..Ann Cardiothorac Surg2018;7:516-20 PMCID:PMC6082785

[22] Head SJ,Taggart DP.Current practice of state-of-the-art surgical coronary revascularization..Circulation2017;136:1331-45

[23] Gaudino M,Taggart DP.Additional arterial conduits in coronary artery bypass surgery: finally coming of age..J Thorac Cardiovasc Surg2018;156:541-3

[24] Motwani JG.Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention..Circulation1998;97:916-31

[25] Hess CN,Gibson CM,Wojdyla DM.Saphenous vein graft failure after coronary artery bypass surgery: insights from PREVENT IV..Circulation2014;130:1445-51 PMCID:PMC4206593

[26] Alexander JH,Harrington RA,Ferguson TB Jr.Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial..JAMA2005;294:2446-54

[27] Alexander JH.Coronary-artery bypass grafting..N Engl J Med2016;374:1954-64

[28] Hindnavis V,Goldberg S.Saphenous vein graft intervention: a review..J Invasive Cardiol2012;24:64-71

[29] Yahagi K,Otsuka F,Davis HR.Pathophysiology of native coronary, vein graft, and in-stent atherosclerosis..Nat Rev Cardiol2016;13:79-98

[30] Sarjeant JM.Understanding and treating vein graft atherosclerosis..Cardiovasc Pathol2002;11:263-71

[31] Lee M.Current state of the art in approaches to saphenous vein graft interventions..Interv Cardiol2017;12:85-91 PMCID:PMC5808481

[32] Davlouros P,Karantalis V,Mavronasiou E.Evaluation of culprit saphenous vein graft lesions with optical coherence tomography in patients with acute coronary syndromes..JACC Cardiovasc Interv2011;4:683-93

[33] Brilakis ES,Cannon CP,Murphy SA.Outcomes of patients with acute coronary syndrome and previous coronary artery bypass grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] trials)..Am J Cardiol2008;102:552-8

[34] Christenson JT,Badel P.Evaluation of preoperative intra-aortic balloon pump support in high risk coronary patients..Eur J Cardiothorac Surg1997;11:1097-103discussion 1104

[35] Morrison DA,Sacks J,Grover F.Percutaneous coronary intervention versus coronary artery bypass graft surgery for patients with medically refractory myocardial ischemia and risk factors for adverse outcomes with bypass: a multicenter, randomized trial. Investigators of the Department of Veterans Affairs Cooperative Study #385, the Angina With Extremely Serious Operative Mortality Evaluation (AWESOME)..J Am Coll Cardiol2001;38:143-9

[36] Fitzgibbon GM,Leach AJ,Hooper GD.Coronary bypass graft fate and patient outcome: angiographic follow-up of 5,065 grafts related to survival and reoperation in 1,388 patients during 25 years..J Am Coll Cardiol1996;28:616-26

[37] Morrison DA,Sacks J,Grover F.Percutaneous coronary intervention versus coronary bypass graft surgery for patients with medically refractory myocardial ischemia and risk factors for adverse outcomes with bypass: the VA AWESOME multicenter registry: comparison with the randomized clinical trial..J Am Coll Cardiol2002;39:266-73

[38] Almomani A,Edupuganti M,Agarwal S.Outcomes of fractional flow reserve-based deferral in saphenous vein graft narrowing..Am J Cardiol2018;122:723-8

[39] Mehilli J.The VELETI II Trial (Sealing Moderate Coronary Saphenous Vein Graft Lesions With Paclitaxel-Eluting Stents): local mechanical intervention fails to stop atheroprogression in saphenous vein grafts..Circ Cardiovasc Interv2016;9:

[40] Mehilli J,Abdel-Wahab M,Byrne RA.Drug-eluting versus bare-metal stents in saphenous vein graft lesions (ISAR-CABG): a randomised controlled superiority trial..Lancet2011;378:1071-8

[41] Brilakis ES,Burke MN.A new treatment strategy for saphenous vein graft lesions?: Letting it Go..J Am Coll Cardiol2018;71:1983-5

[42] Gaudino M,Benedetto U,Di Franco A.Mechanisms, consequences, and prevention of coronary graft failure..Circulation2017;136:1749-64

[43] Avgerinos DV.Hybrid coronary revascularization: present and future..Hellenic J Cardiol2015;56:193-6

[44] Davies MJ.The pathology of myocardial ischaemia..J Clin Pathol Suppl (R Coll Pathol)1977;11:45-52 PMCID:PMC1522223

[45] Puskas JD,DeRose JJ,Miller MA.Hybrid coronary revascularization for the treatment of multivessel coronary artery disease: a multicenter observational study..J Am Coll Cardiol2016;68:356-65 PMCID:PMC5142519

[46] Otsuka F,Sakakura K.Why is the mammary artery so special and what protects it from atherosclerosis?.Ann Cardiothorac Surg2013;2:519-26 PMCID:PMC3741888

[47] Zhang M,Matsuzawa Y,Kwon TG.Left internal mammary artery versus coronary stents: impact on downstream coronary stenoses and conduit patency..J Am Heart Assoc2016;5: PMCID:PMC5079021

[48] Kitamura S.Physiological and metabolic effects of grafts in coronary artery bypass surgery..Circ J2011;75:766-72

[49] ElBardissi AW,Sheng S,Greenberg CC.Trends in isolated coronary artery bypassgrafting: an analysis of the Society of Thoracic Surgeons adult cardiac surgery database..J Thorac Cardiovasc Surg2012;143:273-81

[50] Hlatky MA,Reitz BA,Baker LC.Adoption and effectiveness of internal mammary artery grafting in coronary artery bypass surgery among Medicare beneficiaries..J Am Coll Cardiol2014;63:33-9 PMCID:PMC3947230

[51] Tabata M,Khalpey Z,O’Brien SM.Prevalence and variability of internal mammary artery graft use in contemporary multivessel coronary artery bypass graft surgery: analysis of the Society of Thoracic Surgeons National Cardiac Database..Circulation2009;120:935-40

[52] Diegeler A,Falk V,Spyrantis N.Comparison of stenting with minimally invasive bypass surgery for stenosis of the left anterior descending coronary artery..N Engl J Med2002;347:561-6

[53] Bhatt DL.CABG the clear choice for patients with diabetes and multivessel disease..Lancet2018;391:913-4

[54] Cosgrove DM,Lytle BW,Golding LA.Predictors of reoperation after myocardial revascularization..J Thorac Cardiovasc Surg1986;92:811-21

[55] Head SJ,Daemen J,Boersma E.Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease: a pooled analysis of individual patient data..Lancet2018;391:939-48

[56] Farooq V,Zhang Y,Ståhle E.Short-term and long-term clinical impact of stent thrombosis and graft occlusion in the SYNTAX trial at 5 years: synergy between percutaneous coronary intervention with taxus and cardiac surgery trial..J Am Coll Cardiol2013;62:2360-9

[57] Cassese S,Galasso G,Piscione F.Twelve-month clinical outcomes of everolimus-eluting stent as compared to paclitaxel- and sirolimus-eluting stent in patients undergoing percutaneous coronary interventions. A meta-analysis of randomized clinical trials..Int J Cardiol2011;150:84-9

[58] Onuma Y,Serruys PW.Five-year long-term clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery disease: the SPIRIT II trial..EuroIntervention2013;8:1047-51

[59] Mozaffarian D,Go AS,Blaha MJ.Heart disease and stroke statistics-2016 update: a report from the American Heart Association..Circulation2016;133:e38-360

[60] Pi Y,Holmes DN.Utilization, Characteristics, and In-Hospital Outcomes of Coronary Artery Bypass Grafting in Patients With ST-Segment-Elevation Myocardial Infarction: Results From the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With The Guidelines..Circ Cardiovasc Qual Outcomes2017;10:

[61] Deeik RK,Ihrig TG.Appropriate timing of elective coronary artery bypass graft surgery following acute myocardial infarction..Am J Surg1998;176:581-5

[62] Lee DC,Weinberg AD.Appropriate timing of surgical intervention after transmural acute myocardial infarction..J Thorac Cardiovasc Surg2003;125:115-9discussion 119

[63] Parikh SV,Jessen ME,Ohman EM.Timing of in-hospital coronary artery bypass graft surgery for non-ST-segment elevation myocardial infarction patients results from the National Cardiovascular Data Registry ACTION Registry-GWTG (Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With The Guidelines)..JACC Cardiovasc Interv2010;3:419-27

[64] Thomas MP.Update on primary PCI for patients with STEMI..Trends Cardiovasc Med2017;27:95-102

[65] Chang M,Ahn JM,Sotomi Y.Comparison of outcome of coronary artery bypass grafting versus drug-eluting stent implantation for non-ST-elevation acute coronary syndrome..Am J Cardiol2017;120:380-6

[66] Engstrøm T,Helqvist S,Kløvgaard L.Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease (DANAMI-3-PRIMULTI): an open-label, randomised controlled trial..Lancet2015;386:665-71

[67] Zimarino M,Romanello M,Corazzini A.Complete myocardial revascularization confers a larger clinical benefit when performed with state-of-the-art techniques in high-risk patients with multivessel coronary artery disease: a meta-analysis of randomized and observational studies..Catheter Cardiovasc Interv2016;87:3-12

[68] Chatterjee S,Mukherjee D,Mehran R.Risk of contrast-induced acute kidney injury in ST-elevation myocardial infarction patients undergoing multi-vessel intervention-meta-analysis of randomized trials and risk prediction modeling study using observational data..Catheter Cardiovasc Interv2017;90:205-12

[69] Rosenblum JM,Hoedemaker N,Liberman HA.Hybrid coronary revftascularization versus coronary artery bypass surgery with bilateral or single internal mammary artery grafts..J Thorac Cardiovasc Surg2016;151:1081-9

[70] Kon ZN,Tran R,Reicher B.Simultaneous hybrid coronary revascularization reduces postoperative morbidity compared with results from conventional off-pump coronary artery bypass..J Thorac Cardiovasc Surg2008;135:367-75 PMCID:PMC2962576

[71] Reicher B,Mehra MR,Odonkor P.Simultaneous “hybrid” percutaneous coronary intervention and minimally invasive surgical bypass grafting: feasibility, safety, and clinical outcomes..Am Heart J2008;155:661-7 PMCID:PMC2636970

[72] Giambruno V,Khaliel F,Teefy P.Hybrid coronary revascularization versus on-pump coronary artery bypass grafting..Ann Thorac Surg2018;105:1330-5

[73] Song Z,Zheng Z,Xiong H.One-stop hybrid coronary revascularization versus off-pump coronary artery bypass in patients with diabetes mellitus..J Thorac Cardiovasc Surg2016;151:1695-701.e1691

[74] Kayatta MO,Puskas JD.Hybrid coronary revascularization for the treatment of multivessel coronary artery disease..Ann Cardiothorac Surg2018;7:500-5 PMCID:PMC6082776

[75] Bonatti J,Bonaros N,Zimrin D.Robotically assisted totally endoscopic coronary bypass surgery..Circulation2011;124:236-44 PMCID:PMC3831835

[76] Diegeler A,Metz S,Krakor R.Comparison of MIDCAP versus conventional CABG surgery regarding pain and quality of life..Heart Surg Forum1999;2:290-5discussion 295-6

[77] Verhaegh AJ,van Garsse L.Hybrid coronary revascularization as a safe, feasible, and viable alternative to conventional coronary artery bypass grafting: what is the current evidence?..Minim Invasive Surg2013;2013:142616 PMCID:PMC3649801

[78] De Bruyne B,Kalesan B,Tonino PA.Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease..N Engl J Med2012;367:991-1001

[79] Green KD,Chen TP.Combining PCI and CABG: the role of hybrid revascularization..Curr Cardiol Rep2013;15:351 PMCID:PMC4031750

[80] Serruys PW,Kappetein AP,Holmes DR.Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease..N Engl J Med2009;360:961-72

[81] BARI InvestigatorsThe final 10-year follow-up results from the BARI randomized trial..J Am Coll Cardiol2007;49:1600-6

[82] Head SJ,Mack MJ,Taggart DP.The rationale for Heart Team decision-making for patients with stable, complex coronary artery disease..Eur Heart J2013;34:2510-8

[83] Azzalini L,Puskas JD,Lombardi WL.Percutaneous revascularization of chronic total occlusions: rationale, indications, techniques, and the cardiac surgeon’s point of view..Int J Cardiol2017;231:90-6

[84] Escaned J,Ryan N,Walsh S.Clinical outcomes of state-of-the-art percutaneous coronary revascularization in patients with de novo three vessel disease: 1-year results of the SYNTAX II study..Eur Heart J2017;38:3124-34 PMCID:PMC5837643

[85] Maeremans J,Knaapen P,Avran A.The Hybrid Algorithm for Treating Chronic Total Occlusions in Europe: The RECHARGE Registry..J Am Coll Cardiol2016;68:1958-70

[86] Kufner S,Thannheimer A,Ibrahim T.Ten-year clinical outcomes from a trial of three Limus-eluting stents with different polymer coatings in patients with coronary artery disease..Circulation2019;139:325-33

[87] Barner HB,Reese J.Twelve-year experience with internal mammary artery for coronary artery bypass..J Thorac Cardiovasc Surg1985;90:668-75